CA2840192A1 - Self-renewing endodermal progenitor lines generated from human pluripotent stem cells and methods of use thereof - Google Patents
Self-renewing endodermal progenitor lines generated from human pluripotent stem cells and methods of use thereof Download PDFInfo
- Publication number
- CA2840192A1 CA2840192A1 CA2840192A CA2840192A CA2840192A1 CA 2840192 A1 CA2840192 A1 CA 2840192A1 CA 2840192 A CA2840192 A CA 2840192A CA 2840192 A CA2840192 A CA 2840192A CA 2840192 A1 CA2840192 A1 CA 2840192A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cell
- differentiation
- endoderm
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 210000001778 pluripotent stem cell Anatomy 0.000 title abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 483
- 230000004069 differentiation Effects 0.000 claims description 105
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 93
- 210000001900 endoderm Anatomy 0.000 claims description 84
- 210000000130 stem cell Anatomy 0.000 claims description 37
- 210000001519 tissue Anatomy 0.000 claims description 37
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 28
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 24
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 23
- 210000002304 esc Anatomy 0.000 claims description 21
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 20
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 20
- 230000000968 intestinal effect Effects 0.000 claims description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 17
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 claims description 17
- 102100030243 Transcription factor SOX-17 Human genes 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 241000699670 Mus sp. Species 0.000 claims description 11
- 108010023082 activin A Proteins 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 231100001221 nontumorigenic Toxicity 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 claims description 7
- 101001062347 Homo sapiens Hepatocyte nuclear factor 3-beta Proteins 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 108010083123 CDX2 Transcription Factor Proteins 0.000 claims description 6
- 102000006277 CDX2 Transcription Factor Human genes 0.000 claims description 6
- 101001045740 Homo sapiens Hepatocyte nuclear factor 4-alpha Proteins 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 210000002950 fibroblast Anatomy 0.000 claims description 6
- 102100022054 Hepatocyte nuclear factor 4-alpha Human genes 0.000 claims description 5
- 210000004923 pancreatic tissue Anatomy 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000000638 stimulation Effects 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 101001139130 Homo sapiens Krueppel-like factor 5 Proteins 0.000 claims description 3
- 102100020680 Krueppel-like factor 5 Human genes 0.000 claims description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 3
- 210000005228 liver tissue Anatomy 0.000 claims description 2
- 230000028161 membrane depolarization Effects 0.000 claims description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 101001018100 Homo sapiens Lysozyme C Proteins 0.000 claims 1
- 102100033468 Lysozyme C Human genes 0.000 claims 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 1
- 230000014509 gene expression Effects 0.000 description 59
- 210000003494 hepatocyte Anatomy 0.000 description 41
- 238000000338 in vitro Methods 0.000 description 31
- 230000002441 reversible effect Effects 0.000 description 26
- 230000001052 transient effect Effects 0.000 description 26
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 24
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 24
- 239000002609 medium Substances 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- 108010082117 matrigel Proteins 0.000 description 23
- 238000000684 flow cytometry Methods 0.000 description 22
- 210000004185 liver Anatomy 0.000 description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 230000002440 hepatic effect Effects 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 210000003716 mesoderm Anatomy 0.000 description 16
- 102100029283 Hepatocyte nuclear factor 3-alpha Human genes 0.000 description 15
- 101001062353 Homo sapiens Hepatocyte nuclear factor 3-alpha Proteins 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 13
- 238000011161 development Methods 0.000 description 13
- 230000018109 developmental process Effects 0.000 description 13
- 238000002054 transplantation Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 230000006698 induction Effects 0.000 description 12
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 11
- 206010043276 Teratoma Diseases 0.000 description 11
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 210000000496 pancreas Anatomy 0.000 description 11
- 230000011664 signaling Effects 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 238000002493 microarray Methods 0.000 description 10
- 210000001020 neural plate Anatomy 0.000 description 10
- 230000002062 proliferating effect Effects 0.000 description 10
- 229960004666 glucagon Drugs 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 9
- 229960001225 rifampicin Drugs 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 102000051325 Glucagon Human genes 0.000 description 8
- 108060003199 Glucagon Proteins 0.000 description 8
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 8
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 8
- 238000012423 maintenance Methods 0.000 description 8
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 7
- 108010075254 C-Peptide Proteins 0.000 description 7
- 108700039887 Essential Genes Proteins 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 6
- 102100034850 Peptidyl-prolyl cis-trans isomerase G Human genes 0.000 description 6
- 102000005157 Somatostatin Human genes 0.000 description 6
- 108010056088 Somatostatin Proteins 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 6
- 230000024245 cell differentiation Effects 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 6
- 229960000553 somatostatin Drugs 0.000 description 6
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 6
- 108010075348 Activated-Leukocyte Cell Adhesion Molecule Proteins 0.000 description 5
- 102100024209 CD177 antigen Human genes 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 5
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 5
- 101000980845 Homo sapiens CD177 antigen Proteins 0.000 description 5
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 5
- 101001091194 Homo sapiens Peptidyl-prolyl cis-trans isomerase G Proteins 0.000 description 5
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000013020 embryo development Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000001811 primitive streak Anatomy 0.000 description 5
- 238000009256 replacement therapy Methods 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 4
- 102100024210 CD166 antigen Human genes 0.000 description 4
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 102000009618 Transforming Growth Factors Human genes 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 210000002459 blastocyst Anatomy 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000002771 cell marker Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004039 endoderm cell Anatomy 0.000 description 4
- 210000001654 germ layer Anatomy 0.000 description 4
- 230000004608 intestinal differentiation Effects 0.000 description 4
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000004017 serum-free culture medium Substances 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000005740 tumor formation Effects 0.000 description 4
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- 101000929799 Homo sapiens Acyl-CoA-binding protein Proteins 0.000 description 3
- 101000578254 Homo sapiens Homeobox protein Nkx-6.1 Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 241000204795 Muraena helena Species 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 239000012580 N-2 Supplement Substances 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- -1 bFGF Proteins 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000003890 endocrine cell Anatomy 0.000 description 3
- 230000007045 gastrulation Effects 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 102000045246 noggin Human genes 0.000 description 3
- 108700007229 noggin Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 210000002220 organoid Anatomy 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 108091008023 transcriptional regulators Proteins 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 102100027211 Albumin Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 101150075175 Asgr1 gene Proteins 0.000 description 2
- 102000001493 Cyclophilins Human genes 0.000 description 2
- 108010068682 Cyclophilins Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102100030751 Eomesodermin homolog Human genes 0.000 description 2
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 2
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 2
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 2
- 102100028115 Forkhead box protein P2 Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102100039990 Hairy/enhancer-of-split related with YRPW motif protein 2 Human genes 0.000 description 2
- 101150068639 Hnf4a gene Proteins 0.000 description 2
- 102100024208 Homeobox protein MIXL1 Human genes 0.000 description 2
- 102100028098 Homeobox protein Nkx-6.1 Human genes 0.000 description 2
- 101001064167 Homo sapiens Eomesodermin homolog Proteins 0.000 description 2
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 2
- 101001059881 Homo sapiens Forkhead box protein P2 Proteins 0.000 description 2
- 101001035089 Homo sapiens Hairy/enhancer-of-split related with YRPW motif protein 2 Proteins 0.000 description 2
- 101001052462 Homo sapiens Homeobox protein MIXL1 Proteins 0.000 description 2
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 2
- 101001020548 Homo sapiens LIM/homeobox protein Lhx1 Proteins 0.000 description 2
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 description 2
- 101000603702 Homo sapiens Neurogenin-3 Proteins 0.000 description 2
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 2
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102100036133 LIM/homeobox protein Lhx1 Human genes 0.000 description 2
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 description 2
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101100540835 Mus musculus Wnt3a gene Proteins 0.000 description 2
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 2
- 102100038553 Neurogenin-3 Human genes 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108010070047 Notch Receptors Proteins 0.000 description 2
- 102000005650 Notch Receptors Human genes 0.000 description 2
- 102100040120 Prominin-1 Human genes 0.000 description 2
- 229940121773 Secretase inhibitor Drugs 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 210000002242 embryoid body Anatomy 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 230000020619 endoderm development Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- OGQSCIYDJSNCMY-UHFFFAOYSA-H iron(3+);methyl-dioxido-oxo-$l^{5}-arsane Chemical compound [Fe+3].[Fe+3].C[As]([O-])([O-])=O.C[As]([O-])([O-])=O.C[As]([O-])([O-])=O OGQSCIYDJSNCMY-UHFFFAOYSA-H 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- NGPNWUWGVIIIDG-LEJBHHMKSA-L magnesium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-yl] phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1OP([O-])([O-])=O NGPNWUWGVIIIDG-LEJBHHMKSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 2
- 235000019175 phylloquinone Nutrition 0.000 description 2
- 239000011772 phylloquinone Substances 0.000 description 2
- 229960001898 phytomenadione Drugs 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- LUZOFMGZMUZSSK-LRDDRELGSA-N (-)-indolactam V Chemical compound C1[C@@H](CO)NC(=O)[C@H](C(C)C)N(C)C2=CC=CC3=C2C1=CN3 LUZOFMGZMUZSSK-LRDDRELGSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 1
- 101100502609 Caenorhabditis elegans fem-1 gene Proteins 0.000 description 1
- 102100025745 Cerberus Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102100039203 Cytochrome P450 3A7 Human genes 0.000 description 1
- 102100024810 DNA (cytosine-5)-methyltransferase 3B Human genes 0.000 description 1
- 101710123222 DNA (cytosine-5)-methyltransferase 3B Proteins 0.000 description 1
- 102100021046 DNA-binding protein RFX6 Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 102100035308 Fibroblast growth factor 17 Human genes 0.000 description 1
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 102100036264 Glucose-6-phosphatase catalytic subunit 1 Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102100021374 Hepatocyte nuclear factor 3-gamma Human genes 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 102100028096 Homeobox protein Nkx-6.2 Human genes 0.000 description 1
- 102100038146 Homeobox protein goosecoid Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000799549 Homo sapiens Aspartate aminotransferase, mitochondrial Proteins 0.000 description 1
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 description 1
- 101000914195 Homo sapiens Cerberus Proteins 0.000 description 1
- 101000745715 Homo sapiens Cytochrome P450 3A7 Proteins 0.000 description 1
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 1
- 101001075461 Homo sapiens DNA-binding protein RFX6 Proteins 0.000 description 1
- 101000878124 Homo sapiens Fibroblast growth factor 17 Proteins 0.000 description 1
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 description 1
- 101000930910 Homo sapiens Glucose-6-phosphatase catalytic subunit 1 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000818741 Homo sapiens Hepatocyte nuclear factor 3-gamma Proteins 0.000 description 1
- 101000578258 Homo sapiens Homeobox protein Nkx-6.2 Proteins 0.000 description 1
- 101001032602 Homo sapiens Homeobox protein goosecoid Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000613495 Homo sapiens Paired box protein Pax-4 Proteins 0.000 description 1
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 101000666775 Homo sapiens T-box transcription factor TBX3 Proteins 0.000 description 1
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 1
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 1
- 101000652332 Homo sapiens Transcription factor SOX-1 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101000641959 Homo sapiens Villin-1 Proteins 0.000 description 1
- 101000976653 Homo sapiens Zinc finger protein ZIC 1 Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- LUZOFMGZMUZSSK-UHFFFAOYSA-N Indolactam-V Natural products C1C(CO)NC(=O)C(C(C)C)N(C)C2=CC=CC3=C2C1=CN3 LUZOFMGZMUZSSK-UHFFFAOYSA-N 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- WQZGKKKJIJFFOK-ZZWDRFIYSA-N L-glucose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-ZZWDRFIYSA-N 0.000 description 1
- 101150017554 LGR5 gene Proteins 0.000 description 1
- 108700012912 MYCN Proteins 0.000 description 1
- 101150022024 MYCN gene Proteins 0.000 description 1
- 102100034263 Mucin-2 Human genes 0.000 description 1
- 108010008705 Mucin-2 Proteins 0.000 description 1
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 101150079937 NEUROD1 gene Proteins 0.000 description 1
- 101150111110 NKX2-1 gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101100125896 Neonectria sp. (strain DH2) iliC gene Proteins 0.000 description 1
- 108700020297 NeuroD Proteins 0.000 description 1
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 101150044441 PECAM1 gene Proteins 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 102100040909 Paired box protein Pax-4 Human genes 0.000 description 1
- 102000052651 Pancreatic hormone Human genes 0.000 description 1
- 101800001268 Pancreatic hormone Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101710111200 Peptidyl-prolyl cis-trans isomerase G Proteins 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 241000568452 Sania Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102100038409 T-box transcription factor TBX3 Human genes 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 101150111019 Tbx3 gene Proteins 0.000 description 1
- 208000035199 Tetraploidy Diseases 0.000 description 1
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 1
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 1
- 102100030248 Transcription factor SOX-1 Human genes 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102100033419 Villin-1 Human genes 0.000 description 1
- 102100023497 Zinc finger protein ZIC 1 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004703 blastocyst inner cell mass Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000026287 bud dilation involved in lung branching Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000023011 digestive tract development Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- XHBVYDAKJHETMP-UHFFFAOYSA-N dorsomorphin Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C=CN=CC=2)C=CC=1OCCN1CCCCC1 XHBVYDAKJHETMP-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000023117 embryonic morphogenesis Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 210000003999 epithelial cell of bile duct Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001647 gastrula Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003897 hepatic stem cell Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000004609 intestinal homeostasis Effects 0.000 description 1
- 210000004966 intestinal stem cell Anatomy 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- WDHRPWOAMDJICD-FOAQWNCLSA-N n-[2-[(3'r,3'as,6's,6as,6bs,7'ar,9r,11as,11br)-3',6',10,11b-tetramethyl-3-oxospiro[1,2,4,6,6a,6b,7,8,11,11a-decahydrobenzo[a]fluorene-9,2'-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyridine]-4'-yl]ethyl]-6-(3-phenylpropanoylamino)hexanamide Chemical compound C([C@@H](C)C[C@@H]1[C@@H]2[C@H]([C@]3(C(=C4C[C@@H]5[C@@]6(C)CCC(=O)CC6=CC[C@H]5[C@@H]4CC3)C)O1)C)N2CCNC(=O)CCCCCNC(=O)CCC1=CC=CC=C1 WDHRPWOAMDJICD-FOAQWNCLSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000015031 pancreas development Effects 0.000 description 1
- 239000004025 pancreas hormone Substances 0.000 description 1
- 230000009996 pancreatic endocrine effect Effects 0.000 description 1
- 229940032957 pancreatic hormone Drugs 0.000 description 1
- 210000003134 paneth cell Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000023276 regulation of development, heterochronic Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C12N5/0678—Stem cells; Progenitor cells; Precursor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
- C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0679—Cells of the gastro-intestinal tract
- C12N5/068—Stem cells; Progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161500442P | 2011-06-23 | 2011-06-23 | |
| US61/500,442 | 2011-06-23 | ||
| PCT/US2012/044096 WO2012178215A1 (en) | 2011-06-23 | 2012-06-25 | Self-renewing endodermal progenitor lines generated from human pluripotent stem cells and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2840192A1 true CA2840192A1 (en) | 2012-12-27 |
Family
ID=47423011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2840192A Abandoned CA2840192A1 (en) | 2011-06-23 | 2012-06-25 | Self-renewing endodermal progenitor lines generated from human pluripotent stem cells and methods of use thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9476030B2 (enExample) |
| EP (1) | EP2723851A4 (enExample) |
| JP (1) | JP2014519854A (enExample) |
| AU (1) | AU2012272586B2 (enExample) |
| CA (1) | CA2840192A1 (enExample) |
| WO (1) | WO2012178215A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113913366A (zh) * | 2013-02-18 | 2022-01-11 | 大学健康网络 | 由多能干细胞生成肝细胞和胆管细胞的方法 |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| US10266807B2 (en) | 2013-04-03 | 2019-04-23 | FUJIFILM Cellular Dynamics, Inc. | Methods and compositions for culturing endoderm progenitor cells in suspension |
| EP3712254A1 (en) | 2014-05-28 | 2020-09-23 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| CA2963704A1 (en) | 2014-10-17 | 2016-04-21 | Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
| WO2016145389A1 (en) * | 2015-03-12 | 2016-09-15 | Board Of Trustees Of Michigan State University | Compositions and methods for measuring c-peptide binding and diagnosing immune-mediated diseases |
| EP4177335A1 (en) * | 2016-05-05 | 2023-05-10 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
| EP3483262B1 (en) * | 2016-06-03 | 2021-11-17 | Institue of Transfusion Medicine, Academy of Military Medical Sciences, People's Liberation Army of China | Small molecule compound combination for reprogramming digestive tract derived epithelial cells to endodermal stem/progenitor cells, reprogramming method and application |
| SG11201903697WA (en) | 2016-11-04 | 2019-05-30 | Childrens Hospital Med Ct | Liver organoid compositions and methods of making and using same |
| EP3548507A4 (en) | 2016-12-05 | 2020-07-15 | Children's Hospital Medical Center | COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF |
| EP3583201B1 (en) * | 2017-02-14 | 2024-01-17 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Methods of engineering human induced pluripotent stem cells to produce liver tissue |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| EP3609997A4 (en) | 2017-04-14 | 2021-03-03 | Children's Hospital Medical Center | COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES |
| US12297457B2 (en) | 2017-10-10 | 2025-05-13 | Children's Hospital Medical Center | Esophageal tissue and/or organoid compositions and methods of making same |
| EP3727394A4 (en) | 2017-12-21 | 2021-09-08 | Children's Hospital Medical Center | DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF |
| TWI905079B (zh) * | 2018-04-23 | 2025-11-21 | 日商千紙鶴治療公司 | 增殖抑制劑 |
| US12421500B2 (en) | 2018-07-26 | 2025-09-23 | Children's Hospital Medical Center | Hepato-biliary-pancreatic tissues and methods of making same |
| JP2021535753A (ja) | 2018-09-12 | 2021-12-23 | チルドレンズ ホスピタル メディカル センター | 造血幹細胞およびその派生体の生成のためのオルガノイド組成物 |
| CN111394297A (zh) * | 2018-12-17 | 2020-07-10 | 中国科学院分子细胞科学卓越创新中心 | 内胚层干细胞规模化制备功能性肝母细胞与肝实质细胞的方法及其应用 |
| WO2020160371A1 (en) | 2019-02-01 | 2020-08-06 | The University Of Hong Kong | Innervated organoid compositions and methods of making same |
| US12492380B2 (en) | 2019-05-09 | 2025-12-09 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of hepatocytes |
| CA3141814A1 (en) | 2019-05-31 | 2020-12-03 | Children's Hospital Medical Center | Shaped organoid compositions and methods of making same |
| CN114174494A (zh) | 2019-05-31 | 2022-03-11 | 儿童医院医学中心 | 产生和扩增造血干细胞的方法 |
| EP3980527A4 (en) * | 2019-06-04 | 2023-09-27 | University Health Network | Methods of making and using liver cells |
| CN113265373A (zh) * | 2021-07-19 | 2021-08-17 | 北京明诚创新医学研究院有限责任公司 | 一种人多能干细胞分化为肝祖细胞的培养基、方法及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9700983D0 (sv) * | 1997-03-18 | 1997-03-18 | Ascendia Ab | Stimulering, odling och preservation av pankreas- och andra celler |
| US20060003446A1 (en) * | 2002-05-17 | 2006-01-05 | Gordon Keller | Mesoderm and definitive endoderm cell populations |
| US20080199849A1 (en) * | 2005-09-02 | 2008-08-21 | Agency For Science, Technology And Research | Method of Deriving Progenitor Cell Line |
| EP1941032A2 (en) * | 2005-10-14 | 2008-07-09 | Regents Of The University Of Minnesota | Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype |
| WO2007127454A2 (en) * | 2006-04-28 | 2007-11-08 | Cythera, Inc. | Hepatocyte lineage cells |
| WO2007143193A1 (en) * | 2006-06-02 | 2007-12-13 | University Of Georgia Research Foundation, Inc. | Pancreatic and liver endoderm cells and tissue by differentiation of definitive endoderm cells obtained from human embryonic stems |
| US9029147B2 (en) * | 2007-06-15 | 2015-05-12 | Massachusetts Institute Of Technology | Methods and compositions for enhanced differentiation from embryonic stem cells |
| ES2537578T3 (es) * | 2007-07-18 | 2015-06-09 | Lifescan, Inc. | Diferenciación de las células madre de embriones humanos |
| CN102083967B (zh) * | 2007-07-20 | 2013-05-15 | 塞拉提斯股份公司 | 经由定型内胚层(DE-hep)衍生自人胚泡衍生干细胞的新肝细胞群体 |
| US20090280096A1 (en) * | 2008-05-09 | 2009-11-12 | Atsushi Kubo | Pancreatic endocrine progenitor cells derived from pluripotent stem cells |
| WO2010127367A2 (en) * | 2009-05-01 | 2010-11-04 | Alfagene Bioscience, Inc. | Human gastrointestinal stem cell-derived primary intestinal epithelial cell system and methods of use thereof |
| WO2011005326A1 (en) * | 2009-07-09 | 2011-01-13 | Massachusetts Institute Of Technology | Methods and compositions for increased safety of stem cell-derived populations |
| US20110135610A1 (en) * | 2009-10-30 | 2011-06-09 | The University Of North Carolina At Chapel Hill | Multipotent stem cells from the extrahepatic biliary tree and methods of isolating same |
-
2012
- 2012-06-25 WO PCT/US2012/044096 patent/WO2012178215A1/en not_active Ceased
- 2012-06-25 CA CA2840192A patent/CA2840192A1/en not_active Abandoned
- 2012-06-25 EP EP12802203.5A patent/EP2723851A4/en not_active Withdrawn
- 2012-06-25 JP JP2014517255A patent/JP2014519854A/ja active Pending
- 2012-06-25 AU AU2012272586A patent/AU2012272586B2/en not_active Ceased
-
2013
- 2013-12-23 US US14/138,963 patent/US9476030B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113913366A (zh) * | 2013-02-18 | 2022-01-11 | 大学健康网络 | 由多能干细胞生成肝细胞和胆管细胞的方法 |
| CN113913366B (zh) * | 2013-02-18 | 2025-01-10 | 大学健康网络 | 由多能干细胞生成肝细胞和胆管细胞的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012272586B2 (en) | 2016-07-07 |
| EP2723851A4 (en) | 2015-05-20 |
| WO2012178215A1 (en) | 2012-12-27 |
| EP2723851A1 (en) | 2014-04-30 |
| AU2012272586A1 (en) | 2014-01-16 |
| US9476030B2 (en) | 2016-10-25 |
| JP2014519854A (ja) | 2014-08-21 |
| US20140141509A1 (en) | 2014-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012272586B2 (en) | Self-renewing endodermal progenitor lines generated from human pluripotent stem cells and methods of use thereof | |
| Cheng et al. | Self-renewing endodermal progenitor lines generated from human pluripotent stem cells | |
| Shim et al. | Directed differentiation of human embryonic stem cells towards a pancreatic cell fate | |
| US10266807B2 (en) | Methods and compositions for culturing endoderm progenitor cells in suspension | |
| KR102453717B1 (ko) | 원시 장 내배엽 세포 및 그 제작 방법 | |
| Blyszczuk et al. | Embryonic stem cells differentiate into insulin-producing cells without selection of nestin-expressing cells | |
| US8685730B2 (en) | Methods and devices for differentiating pluripotent stem cells into cells of the pancreatic lineage | |
| JP5882226B2 (ja) | ヒト胚性幹細胞の分化 | |
| JP5843775B2 (ja) | 幹細胞を分化させるための重量オスモル濃度の操作法 | |
| CN102791851B (zh) | 纯化衍生自多能干细胞的细胞的方法 | |
| US20050032207A1 (en) | Method for isolating, culturing and differentiating intestinal stem cells for therapeutic use | |
| Kania et al. | Differentiation of mouse embryonic stem cells into pancreatic and hepatic cells | |
| CN110392735A (zh) | 胰腺祖细胞的维持和扩增 | |
| Ghezelayagh et al. | Improved differentiation of hESC-derived pancreatic progenitors by using human fetal pancreatic mesenchymal cells in a micro‐scalable three-dimensional co-culture system | |
| EP3868870A1 (en) | Method for producing stem/precursor cells, by using low molecular weight compound, from cells derived from endodermal tissue or organ | |
| EP4227402A1 (en) | Method for inducing differentiated cells into pluripotent endoderm stem cells and application thereof | |
| Sato et al. | Induction of Differentiation into Endoderm, Insulin-Secreting Cells from Mouse Embryonic Stem Cells Using Activin A and Retinoic Acid | |
| Subramanian | Engineering pluripotent stem cells for the fabrication of biomimetic liver-like tissue | |
| Smukler | Stem Cells of the Neural and Pancreatic Lineages | |
| Salar | Culture, maintenance and control of mouse embryonic stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170623 |
|
| FZDE | Discontinued |
Effective date: 20191113 |